Comparative Pharmacology
Head-to-head clinical analysis: DANZITEN versus FLUOXYMESTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANZITEN versus FLUOXYMESTERONE.
DANZITEN vs FLUOXYMESTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), preventing export of tumor suppressor proteins and growth regulators from the nucleus, leading to cell cycle arrest and apoptosis.
Synthetic androgen receptor agonist; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
1.5 mg orally once daily, increased at 2-week intervals to 3 mg once daily, then 5 mg once daily based on tolerability and efficacy.
Adults: 5-20 mg orally once daily. For replacement therapy, 5-10 mg daily; for hypogonadism, 5-20 mg daily for several months.
None Documented
None Documented
Clinical Note
moderateAcarbose + Fluoxymesterone
"Acarbose may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderateSunitinib + Fluoxymesterone
"Sunitinib may increase the hypoglycemic activities of Fluoxymesterone."
Clinical Note
moderatePrednisolone + Fluoxymesterone
"Prednisolone may increase the fluid retaining activities of Fluoxymesterone."
Clinical Note
moderateDexamethasone + Fluoxymesterone
Approximately 10-12 hours in adults; may be prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life: 9.2 hours; clinical context: supports once-daily dosing for androgen replacement, with steady-state achieved in ~2 days
Primarily hepatic metabolism followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%
Category C
Category C
Androgen/Antigonadotropin
Androgen
"Dexamethasone may increase the fluid retaining activities of Fluoxymesterone."